Claire E. Kaple, Sarah N. Redmond, Jennifer L. Cadnum, Bryan Hausman, Munok Hwang, Hosoon Choi, Piyali Chatterjee, Chetan Jinadatha, Curtis J. Donskey
ABSTRACT The clinical significance of Clostridioides difficile isolates with reduced fidaxomicin susceptibility is uncertain. We report treatment failure of extended-pulsed fidaxomicin treatment during every other day pulsing associated with emergence of a C. difficile isolate with reduced fidaxomicin susceptibility and a novel rpoC gene mutation, resulting in a novel amino acid substitution (R89K). The reduced susceptibility isolate had no reduction in growth or ability to colonize mice, but in vitro sporulation and toxin production were reduced.